Virax Biolabs (VRAX) Accounts Payables (2021 - 2023)

Virax Biolabs (VRAX) has 3 years of Accounts Payables data on record, last reported at $159908.0 in Q1 2023.

  • For Q1 2023, Accounts Payables fell 81.11% year-over-year to $159908.0; the TTM value through Mar 2023 reached $159908.0, down 81.11%, while the annual FY2023 figure was $159908.0, 81.11% down from the prior year.
  • Accounts Payables reached $159908.0 in Q1 2023 per VRAX's latest filing, down from $846474.0 in the prior quarter.
  • Across five years, Accounts Payables topped out at $846474.0 in Q1 2022 and bottomed at $159908.0 in Q1 2023.
  • Average Accounts Payables over 3 years is $407842.3, with a median of $217145.0 recorded in 2021.
  • Peak YoY movement for Accounts Payables: surged 289.82% in 2022, then crashed 81.11% in 2023.
  • A 3-year view of Accounts Payables shows it stood at $217145.0 in 2021, then soared by 289.82% to $846474.0 in 2022, then plummeted by 81.11% to $159908.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $159908.0 in Q1 2023, $846474.0 in Q1 2022, and $217145.0 in Q1 2021.